-->

Tag: Accelerated approval 2024

Home / Accelerated approval 2024

Categories

Tarlatamab-dlle is granted accelerated approval by FDA for extensive stage small cell lung cancer

May 2024: Tarlatamab-dlle (Imdelltra, Amgen, Inc.) has received fast approval from the Food and Drug Administration for the treatment of extensive stage small cell lung cancer (ES-SCLC) in patients wh...
accelerated-approval-2024

Ponatinib with chemotherapy has received accelerated approval by the USFDA for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

March 2024: Ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A., Inc.) has received fast approval from the Food and Drug Administration for use in combination with chemotherapy in adult patients who hav...
accelerated-approval-2024

Scan the code